Previous 10 | Next 10 |
NEW YORK, Feb. 24, 2022 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today reported financial results and operational highlights for the period ended December 31, 2021. Financial Highlights ...
NEW YORK, Feb. 20, 2022 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced positive results from an interim analysis of the first patient cohort in the randomized, controlled study of remest...
Mesoblast (NASDAQ:MESO) appoints Dr. Eric Rose as the Company’s Chief Medical Officer (CMO). Dr. Rose has been a non-executive director of Mesoblast since 2013. Dr. Rose is a highly respected physician scientist with focus on clinical investigation, drug discovery, biodefense, and heal...
NEW YORK, Feb. 01, 2022 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, is pleased to announce the appointment of Dr. Eric Rose as the Company’s Chief Medical Officer (CMO). Dr. Rose has been a non...
NEW YORK, Jan. 24, 2022 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, announced today it is participating in Edison Group’s Open House Event, scheduled to take place virtually this week. The thr...
NEW YORK, Jan. 11, 2022 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced 36-month follow-up results from the 404-patient Phase 3 trial of its allogeneic cell therapy rexlemestrocel-L (MPC-...
Palm Beach, FL – January 5, 2022 – FinancialNewsMedia.com News Commentary – Alzheimer’s disease (AD) is the most common reason of progressive dementia in the elderly population. There has been an exponential rise in the number of cases of Alzheimer...
Key Points: Meeting held with the US Food and Drug Administration’s (FDA) Office of Tissues and Advanced Therapies (OTAT) to address potency assay and chemistry, manufacturing and controls (CMC) items identified in the complete response letter (CRL) for remestemcel-L in t...
Calliditas Therapeutics (NASDAQ:CALT) +38% on FDA approval for kidney disease therapy. Kaixin Auto (NASDAQ:KXIN) +27% on a partnership agreement with Bujia for 10k new energy trucks. Biomerica (NASDAQ:BMRA) +18% preliminary second quarter revenue increase of approxima...
Mesoblast (NASDAQ:MESO) has received feedback from the FDA's Office of Tissues and Advanced Therapies (OTAT) on the Phase 3 program of rexlemestrocel-L in patients with chronic low back pain due to degenerative disc disease refractory to available therapies, including opioids. Following revie...
News, Short Squeeze, Breakout and More Instantly...
2024-07-23 14:15:03 ET Piper Sandler analyst issues OVERWEIGHT recommendation for MESO on July 23, 2024 12:57PM ET. MESO was trading at $8.29 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst recommendations are : 5 - Buy, 2 - H...
NEW YORK, July 23, 2024 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, announced that the United States Food and Drug Administration (FDA) has accepted its Biologics License Application (BLA) resubmission for...
NEW YORK, July 21, 2024 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, announced today that the confirmatory Phase 3 trial of its allogeneic, immunoselected, and industrially manufactured stromal cell product...